Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login



COVID-19 vaccines: send us your questions

With positive trial results for potential COVID-19 vaccines coming thick and fast, we plan to dig beneath the headlines and answer your questions.

Covid-19 vaccines

Source: Mclean/

The Pharmaceutical Journal wants to answer your questions on the potential COVID-19 vaccines

Positive results from phase III trials of three potential COVID-19 vaccines have been announced this month. First came data from Pfizer/BioNTech and Moderna, with both reporting an impressive more than 90% efficacy for their mRNA vaccines. Next was Oxford University/AstraZeneca, which announced an overall efficacy of 70%, with one regimen achieving 90% protection from COVID-19 symptoms.

The UK government has pre-ordered 145 million of these vaccines altogether and there are plans to begin a massive vaccination programme as soon as the Medicines and Healthcare products Regulatory Agency gives the green light to Pfizer/BioNTech or Oxford/AstraZeneca, both of which have doses ready to go.

Pharmacists will be among the first on the priority list to receive these vaccines and will, undoubtedly, play some role in administering them. We want to dig beneath the headlines and answer your burning questions on the vaccines. Ask us anything about the science, development, approval, distribution, storage or administration of the vaccines, or about what’s in the pipeline, and we’ll do our best to get you the answers. Don’t hold back, fill in the form below.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20208582

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.